Related Experiment Video
Updated: May 22, 2026
09:40
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Oxaliplatin-related thrombocytopenia
D L Jardim1, C A Rodrigues2, Y A S Novis1
1Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo.
Summary
Oxaliplatin chemotherapy can cause low platelet counts (thrombocytopenia) through bone marrow suppression, liver damage, or immune reactions. Understanding these mechanisms is key for managing this common side effect.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Oxaliplatin is a platinum-based chemotherapy agent used for various cancers, including colorectal cancer.
- Thrombocytopenia (low platelet count) is a frequent and dose-limiting toxicity of oxaliplatin treatment, affecting up to 70% of patients.
- Traditional understanding attributes oxaliplatin-induced thrombocytopenia primarily to myelosuppression.
Purpose of the Study:
- To review the emerging mechanisms of oxaliplatin-related thrombocytopenia beyond myelosuppression.
- To provide clinical insights into the management of this significant chemotherapy side effect.
Main Methods:
- Literature review of studies on oxaliplatin toxicity and thrombocytopenia.
- Analysis of emerging pathophysiological pathways and clinical presentations.
Main Results:
- Oxaliplatin-induced thrombocytopenia can result from splenic platelet sequestration due to liver damage.
- Immune-mediated thrombocytopenia is another identified mechanism.
- These alternative pathways present distinct clinical courses and may require tailored management strategies.
Conclusions:
- Oxaliplatin-related thrombocytopenia involves complex mechanisms including myelosuppression, liver-induced sequestration, and immune responses.
- Recognizing these diverse pathways is crucial for effective clinical management and patient care.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...